Responses
Oncology
Protocol
Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study
Compose a Response to This Article
Other responses
No responses have been published for this article.